HK1126390A1 - Use of citrulline in the manufacture of a medicament for the correction of arginine deficiency in septic patients - Google Patents

Use of citrulline in the manufacture of a medicament for the correction of arginine deficiency in septic patients

Info

Publication number
HK1126390A1
HK1126390A1 HK09104767.4A HK09104767A HK1126390A1 HK 1126390 A1 HK1126390 A1 HK 1126390A1 HK 09104767 A HK09104767 A HK 09104767A HK 1126390 A1 HK1126390 A1 HK 1126390A1
Authority
HK
Hong Kong
Prior art keywords
citrulline
arginine
medicament
correction
manufacture
Prior art date
Application number
HK09104767.4A
Other languages
English (en)
Inventor
Nicolaas Emile Deutz
Norman Alan Greenberg
Kala Marie Kaspar
Candis Kvamme
Yvette Charlotte Luiking
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of HK1126390A1 publication Critical patent/HK1126390A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
HK09104767.4A 2006-04-04 2009-05-26 Use of citrulline in the manufacture of a medicament for the correction of arginine deficiency in septic patients HK1126390A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78933006P 2006-04-04 2006-04-04
US74749306P 2006-05-17 2006-05-17
PCT/US2007/008143 WO2007114903A2 (en) 2006-04-04 2007-04-02 Treatments using citrulline

Publications (1)

Publication Number Publication Date
HK1126390A1 true HK1126390A1 (en) 2009-09-04

Family

ID=38461725

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104767.4A HK1126390A1 (en) 2006-04-04 2009-05-26 Use of citrulline in the manufacture of a medicament for the correction of arginine deficiency in septic patients

Country Status (13)

Country Link
US (1) US20090291877A1 (ru)
EP (3) EP2612666A3 (ru)
JP (2) JP2009533342A (ru)
CN (1) CN102935231A (ru)
AU (1) AU2007233371B2 (ru)
BR (1) BRPI0710044A2 (ru)
CA (2) CA2648126C (ru)
HK (1) HK1126390A1 (ru)
IL (1) IL194202A0 (ru)
MX (1) MX2008012723A (ru)
RU (1) RU2444355C2 (ru)
WO (1) WO2007114903A2 (ru)
ZA (1) ZA200809393B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
CA2702045C (en) 2007-10-10 2017-07-25 Kyowa Hakko Bio Co., Ltd. Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine
ITMI20080567A1 (it) * 2008-04-02 2009-10-03 Androsystems Srl L-citrullina per il trattamento della disfunzione endoteliale e della disfunzione erettile.
CN102215837B (zh) 2008-09-19 2014-04-30 雀巢产品技术援助有限公司 预防和/或减轻癌性肿瘤的骨髓毒性的营养支持
CN105876780A (zh) 2008-09-19 2016-08-24 雀巢产品技术援助有限公司 抗癌治疗中的免疫系统营养支持
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
WO2011019641A2 (en) * 2009-08-13 2011-02-17 Nestec S.A. Nutritional compositions including exogenous nucleotides
FR2970414B1 (fr) * 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
US20140037604A1 (en) * 2011-04-18 2014-02-06 Nestec S.A. Nutritional compositions comprising alpha-hydroxyisocaproic acid
JP2013060406A (ja) * 2011-09-15 2013-04-04 Kyowa Hakko Bio Co Ltd 脳疲労改善用経口剤
WO2013063533A1 (en) * 2011-10-26 2013-05-02 Clinical And Herbal Innovations, Inc. Dietary supplement for vascular health
US20150025147A1 (en) * 2012-03-02 2015-01-22 Kyowa Hakko Bio Co., Ltd Enhancer for eating activity and/or gastrointestinal activity
JP6876632B2 (ja) * 2015-06-29 2021-05-26 バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 手術中のシトルリン静脈内投与
JP6357625B2 (ja) * 2015-07-23 2018-07-18 テクノサイエンス株式会社 栄養補助食品用の組成物
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
JP2016121194A (ja) * 2016-04-05 2016-07-07 協和発酵バイオ株式会社 脳疲労改善用経口剤
JP2018119017A (ja) * 2018-05-16 2018-08-02 テクノサイエンス株式会社 栄養補助食品用の組成物
EP4142520A1 (en) * 2020-04-29 2023-03-08 Société des Produits Nestlé S.A. A nutritional product containing a buffer composition and an amino acid and methods of using such a nutritional product
CN112868919B (zh) * 2021-02-25 2023-01-17 新疆农业大学 一种提升公羊精液品质的饲料及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096254A (en) * 1976-05-10 1978-06-20 Richardson-Merrell Inc. Method of treating the symptoms of menopause and osteoporosis
US5411757A (en) * 1989-11-09 1995-05-02 Buist; Neil R. M. Palatable balanced amino acid-modified diet
CA2116684A1 (en) * 1991-09-27 1993-04-01 Robert G. Kilbourn Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5356873A (en) * 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
CA2348741C (en) * 1998-10-30 2010-04-20 Nitromed Inc. Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
ATE308254T1 (de) * 1998-12-15 2005-11-15 Nestle Sa Ballaststoffemischung für enterale zusammensetzung
US20020193342A1 (en) 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
JPWO2004052125A1 (ja) * 2002-12-06 2006-04-06 協和醗酵工業株式会社 アミノ酸を含有する飲料およびアミノ酸の苦味を低減する方法
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale
WO2005107735A2 (en) * 2004-04-30 2005-11-17 Pump Formulations, Ltd. Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a
WO2006002096A2 (en) * 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Low doses of l-citrulline for treating diseases
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease

Also Published As

Publication number Publication date
MX2008012723A (es) 2008-10-14
IL194202A0 (en) 2009-09-22
AU2007233371A1 (en) 2007-10-11
CA2648126C (en) 2012-12-18
JP2009533342A (ja) 2009-09-17
EP2612666A3 (en) 2013-10-02
US20090291877A1 (en) 2009-11-26
BRPI0710044A2 (pt) 2011-08-02
EP2004171A2 (en) 2008-12-24
WO2007114903A2 (en) 2007-10-11
ZA200809393B (en) 2009-12-30
EP2612666A2 (en) 2013-07-10
CN102935231A (zh) 2013-02-20
CA2648126A1 (en) 2007-10-11
WO2007114903A3 (en) 2008-02-14
RU2444355C2 (ru) 2012-03-10
RU2008143310A (ru) 2010-05-10
JP2012197283A (ja) 2012-10-18
CA2778823A1 (en) 2007-10-11
EP2679223A1 (en) 2014-01-01
AU2007233371B2 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
HK1126390A1 (en) Use of citrulline in the manufacture of a medicament for the correction of arginine deficiency in septic patients
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
MY151018A (en) Use of nutritional compositions for preventing disorders
HK1141237A1 (en) Glp-1-fc fusion protein formulation glp-1-fc
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
MY176679A (en) Use of nutritional compositions for preventing disorders
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
MY156243A (en) Treatment for diabetes in patients inappropriate for metformin therapy
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
DE602005024352D1 (de) Implantate zur Flüssigkeitsbehandlung mit verbesserter Verschlussbeständigkeit
MY153408A (en) Novel methods
BRPI0509210A (pt) uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono
MX2013008729A (es) Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
WO2007130501A3 (en) Combination therapy for treatment of cancer
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
SE0700456L (sv) Injicerbar suspension innefattande titan-,titanlegerings- eller titanoxidpartiklar av mikrostruktur
ATE539764T1 (de) Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
WO2012016229A3 (en) Oxytocin treatment to improve memory and modify blood glucose
MX2010003615A (es) Tratamiento de desordenes neurologicos.
EA200601853A1 (ru) Лечение нарушенной дыхательной функции
MX2009003676A (es) Compuestos s-nitrosotiol y derivados relacionados.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170402